Moleculin Biotech, Inc.
MBRX Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025
Revenue
Total sales reported in the income statement.
$0.0M
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$33.6M
Free cash flow
Cash from operations minus capital spending.
−$22.7M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
What Moleculin Biotech, Inc. does
No business description yet.
- Legal name
- Moleculin Biotech, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Accession · CIK
- 0001437749-26-008841
0001659617
Revenue and margins
Moleculin Biotech, Inc. had $0.0M of revenue in fiscal 2025.
FY16
Revenue $0.0M
FY17
Revenue $0.0M
FY18
Revenue $0.0M
FY19
Revenue $0.0M
FY20
Revenue $0.0M
FY21
Revenue $0.0M
FY22
Revenue $0.0M
FY23
Revenue $0.0M
FY24
Revenue $0.0M
FY25
Revenue $0.0M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY16
Gross —
Operating —
Net —
FCF —
FY17
Gross —
Operating —
Net —
FCF —
FY18
Gross —
Operating —
Net —
FCF —
FY19
Gross —
Operating —
Net —
FCF —
FY20
Gross —
Operating —
Net —
FCF —
FY21
Gross —
Operating —
Net —
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY16
Net income −$3.9M
FY17
Net income −$9.8M
FY18
Net income −$11.9M
FY19
Net income −$13.2M
FY20
Net income −$17.4M
FY21
Net income −$15.9M
FY22
Net income −$29.0M
FY23
Net income −$29.8M
FY24
Net income −$26.0M
FY25
Net income −$33.6M
Q3 '23
Net income −$5.6M
Q4 '23
Net income −$10.3M
Q1 '24
Net income −$6.4M
Q2 '24
Net income −$6.0M
Q3 '24
Net income −$7.0M
Q4 '24
Net income −$6.6M
Q1 '25
Net income −$5.9M
Q2 '25
Net income −$17.8M
Q3 '25
Net income −$25.4M
Q4 '25
Net income $15.6M
Q1 '26
Net income −$12.8M
Q2 '26
Net income −$7.6M
FY16
Diluted EPS −$0.40
FY17
Diluted EPS −$0.53
FY18
Diluted EPS −$0.46
FY19
Diluted EPS −$1.95
FY20
Diluted EPS −$1.76
FY21
Diluted EPS −$0.59
FY22
Diluted EPS —
FY23
Diluted EPS —
FY24
Diluted EPS —
FY25
Diluted EPS —
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital —
Return on equity −26.2%
Return on assets −23.9%
FY17
Return on capital —
Return on equity −61.1%
Return on assets −54.7%
FY18
Return on capital —
Return on equity −75.7%
Return on assets −60.8%
FY19
Return on capital —
Return on equity −88.5%
Return on assets −58.9%
FY20
Return on capital —
Return on equity −104.1%
Return on assets −64.0%
FY21
Return on capital —
Return on equity −32.9%
Return on assets −28.1%
FY22
Return on capital —
Return on equity −44.3%
Return on assets −41.0%
FY23
Return on capital —
Return on equity −71.6%
Return on assets −62.3%
FY24
Return on capital —
Return on equity −123.6%
Return on assets −94.5%
FY25
Return on capital —
Return on equity −256.0%
Return on assets −171.9%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$22.7M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY16
Free cash flow −$3.8M
FY17
Free cash flow −$7.4M
FY18
Free cash flow −$12.6M
FY19
Free cash flow −$17.3M
FY20
Free cash flow −$18.1M
FY21
Free cash flow −$19.0M
FY22
Free cash flow −$27.7M
FY23
Free cash flow −$23.7M
FY24
Free cash flow −$23.9M
FY25
Free cash flow −$22.7M
Q3 '23
Free cash flow −$7.6M
Q4 '23
Free cash flow −$5.0M
Q1 '24
Free cash flow −$6.7M
Q2 '24
Free cash flow −$6.0M
Q3 '24
Free cash flow −$6.1M
Q4 '24
Free cash flow −$5.1M
Q1 '25
Free cash flow −$4.6M
Q2 '25
Free cash flow −$5.6M
Q3 '25
Free cash flow −$7.2M
Q4 '25
Free cash flow −$5.4M
Q1 '26
Free cash flow —
Q2 '26
Free cash flow —
FY16
Cash from operations −$3.8M
Capital spending $0.0M
FY17
Cash from operations −$7.3M
Capital spending $0.0M
FY18
Cash from operations −$12.2M
Capital spending $0.4M
FY19
Cash from operations −$17.2M
Capital spending $0.1M
FY20
Cash from operations −$17.8M
Capital spending $0.4M
FY21
Cash from operations −$19.0M
Capital spending $0.0M
FY22
Cash from operations −$27.6M
Capital spending $0.1M
FY23
Cash from operations −$23.6M
Capital spending $0.1M
FY24
Cash from operations −$23.9M
Capital spending $0.0M
FY25
Cash from operations −$22.7M
Capital spending $0.0M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$7.6M
Capital spending $0.0M
Q4 '23
Cash from operations −$4.9M
Capital spending $0.1M
Q1 '24
Cash from operations −$6.7M
Capital spending $0.0M
Q2 '24
Cash from operations −$5.9M
Capital spending $0.0M
Q3 '24
Cash from operations −$6.1M
Capital spending $0.0M
Q4 '24
Cash from operations −$5.1M
Capital spending $0.0M
Q1 '25
Cash from operations −$4.6M
Capital spending $0.0M
Q2 '25
Cash from operations −$5.6M
Capital spending $0.0M
Q3 '25
Cash from operations −$7.2M
Capital spending $0.0M
Q4 '25
Cash from operations −$5.4M
Capital spending $0.0M
Q1 '26
Cash from operations −$6.1M
Capital spending —
Q2 '26
Cash from operations −$6.7M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
Moleculin Biotech, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY16
Dividends —
Buybacks —
FY17
Dividends —
Buybacks —
FY18
Dividends —
Buybacks —
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY16
Diluted shares 0.01B
FY17
Diluted shares 0.02B
FY18
Diluted shares 0.03B
FY19
Diluted shares 0.01B
FY20
Diluted shares 0.01B
FY21
Diluted shares 0.03B
FY22
Diluted shares —
FY23
Diluted shares —
FY24
Diluted shares —
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Moleculin Biotech, Inc. can carry it.
FY16
Cash $5.0M
Debt —
FY17
Cash $7.7M
Debt —
FY18
Cash $7.1M
Debt —
FY19
Cash $10.7M
Debt —
FY20
Cash $15.2M
Debt —
FY21
Cash $70.9M
Debt —
FY22
Cash $43.1M
Debt —
FY23
Cash $23.6M
Debt —
FY24
Cash $4.3M
Debt —
FY25
Cash $8.9M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M |
| Current ratio | 20.0x | 9.5x | 3.9x | 1.0x | 1.4x |
| Quick ratio | 20.0x | 9.5x | 3.9x | 1.0x | 1.4x |
| Total assets | $84.1M | $57.4M | $38.2M | $16.9M | $22.1M |
| Total liabilities | $5.1M | $5.2M | $12.1M | $5.7M | $7.1M |
| Shareholders' equity | $79.0M | $52.2M | $30.9M | $11.2M | $15.0M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✕ | ✓ | ✕ | ✓ | ✕ | ✕ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — | — | — | — | — | — |
| Current ratio rose | — | ✕ | ✕ | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✓ | ✕ | ✕ | — | — | — | — |
| Gross margin rose | — | — | — | — | — | — | — | — | — | — |
| Revenue rose relative to assets | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| F-score | — / 3 | 1 / 7 | 0 / 7 | 3 / 7 | 1 / 7 | 2 / 7 | — / 6 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −1.0% | −13.8% | 1.7% | 17.8% | 1.5% | 5.4% | −2.0% | −12.9% | −7.9% | −55.4% |
| Altman Z'' | 9.99 | 4.24 | −5.35 | −5.51 | −6.08 | 16.99 | 5.77 | −10.42 | −41.80 | −34.92 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net interest income | — | $0.0M | $0.0M | $0.0M | $0.0M | $0.3M | $0.2M | — | — | — |
| Research and development | $1.5M | $4.5M | $9.7M | $11.0M | $12.8M | $14.4M | $19.0M | $19.5M | $17.7M | $15.9M |
| Operating income | −$3.9M | −$8.7M | −$15.0M | −$17.5M | −$19.7M | −$23.0M | −$30.6M | −$29.6M | −$26.6M | −$25.1M |
| Interest expense | $0.0M | $0.0M | — | — | — | — | — | — | — | — |
| Pretax income | — | — | — | −$13.4M | −$17.4M | — | — | — | −$26.0M | −$33.6M |
| Income tax | $0.0M | $0.0M | $0.0M | −$0.2M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$3.9M | −$9.8M | −$11.9M | −$13.2M | −$17.4M | −$15.9M | −$29.0M | −$29.8M | −$26.0M | −$33.6M |
| Net income to common | — | — | — | — | — | — | — | — | −$26.0M | −$33.7M |
| Diluted EPS | −$0.40 | −$0.53 | −$0.46 | −$1.95 | −$1.76 | −$0.59 | — | — | — | — |
| Diluted shares | 0.01B | 0.02B | 0.03B | 0.01B | 0.01B | 0.03B | — | — | — | — |
| Cash flow | ||||||||||
| Cash from operations | −$3.8M | −$7.3M | −$12.2M | −$17.2M | −$17.8M | −$19.0M | −$27.6M | −$23.6M | −$23.9M | −$22.7M |
| Capital expenditure | $0.0M | $0.0M | $0.4M | $0.1M | $0.4M | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$3.8M | −$7.4M | −$12.6M | −$17.3M | −$18.1M | −$19.0M | −$27.7M | −$23.7M | −$23.9M | −$22.7M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $0.2M | $0.2M | $0.2M | $0.1M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $0.3M | $0.7M | $1.1M | $1.5M | $1.7M | $2.4M | $2.3M | $2.0M | $1.7M | $1.7M |
| Acquisitions | $0.1M | $0.0M | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||||
| Cash and short-term investments | $5.0M | $7.7M | $7.1M | $10.7M | $15.2M | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M |
| Current assets | $5.2M | $8.3M | $8.0M | $13.5M | $17.2M | $72.5M | $45.6M | $26.3M | $5.2M | $9.7M |
| Current liabilities | $1.3M | $2.2M | $3.9M | $3.6M | $2.9M | $3.6M | $4.8M | $6.8M | $5.4M | $6.9M |
| Property and equipment, net | $0.0M | $0.0M | $0.5M | $0.3M | $0.5M | $0.3M | $0.3M | $0.3M | $0.2M | $0.1M |
| Total assets | $16.4M | $19.5M | $19.6M | $25.2M | $29.0M | $84.1M | $57.4M | $38.2M | $16.9M | $22.1M |
| Total liabilities | $1.4M | $2.4M | $5.3M | $9.7M | $11.3M | $5.1M | $5.2M | $12.1M | $5.7M | $7.1M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $15.0M | $17.1M | $14.3M | $15.6M | $17.8M | $79.0M | $52.2M | $30.9M | $11.2M | $15.0M |
| Returns | ||||||||||
| Return on capital employed | −25.8% | −50.1% | −95.7% | −80.9% | −75.6% | −28.5% | −58.2% | −94.4% | −230.3% | −164.4% |
| Return on equity | −26.2% | −61.1% | −75.7% | −88.5% | −104.1% | −32.9% | −44.3% | −71.6% | −123.6% | −256.0% |
| Return on assets | −23.9% | −54.7% | −60.8% | −58.9% | −64.0% | −28.1% | −41.0% | −62.3% | −94.5% | −171.9% |
| Return on tangible equity | −26.2% | −57.3% | −83.2% | −84.8% | −97.7% | −20.1% | −55.6% | −96.3% | −232.4% | −224.3% |
| Growth | ||||||||||
| Share count change | — | 89.0% | 39.5% | −73.8% | 45.1% | 173.0% | — | — | — | — |
| Financial health | ||||||||||
| Interest coverage | −90.3x | — | — | — | — | — | — | — | — | — |
| Current ratio | 3.9x | 3.7x | 2.1x | 3.8x | 5.9x | 20.0x | 9.5x | 3.9x | 1.0x | 1.4x |
| Quick ratio | 3.9x | 3.7x | 2.1x | 3.8x | 5.9x | 20.0x | 9.5x | 3.9x | 1.0x | 1.4x |
| Quality scores | ||||||||||
| Piotroski F-score | — | 1.0 | 0.0 | 3.0 | 1.0 | 2.0 | — | — | — | — |
| Altman Z'' | 10.0 | 4.2 | −5.3 | −5.5 | −6.1 | 17.0 | 5.8 | −10.4 | −41.8 | −34.9 |
| Accruals ratio | −1.0% | −13.8% | 1.7% | 17.8% | 1.5% | 5.4% | −2.0% | −12.9% | −7.9% | −55.4% |
Source: SEC EDGAR XBRL filings (CIK 0001659617). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.